15 December 2020 : Clinical Research
Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma
Yu Qian1ABCDEF, Jing-Wen Wang1BC, Yu Fang1BCD, Xiao-Dong Yuan1B, Yu-Chen Fan12ADF, Shuai Gao12CDFG, Kai Wang12ADEG*DOI: 10.12659/MSM.927444
Med Sci Monit 2020; 26:e927444
Table 4 Diagnostic utility of AFP, CCND2 promoter methylation, and combined measurement for discrimination of HCC from LC and CHB.
| Parameter | CCND2 methylation | AFP | AFP+CCND2 methylation | P-value | |||
|---|---|---|---|---|---|---|---|
| PBMCs | Plasma | PBMCs | Plasma | PBMCs | Plasma | ||
| Se (%) | 55/118 (46.61) | 52/118 (44.07) | 68/118 (57.63) | 97/118 (82.20) | 96/118 (81.36) | <0.001* | <0.001* |
| Sp (%) | 39/47 (82.98) | 42/47 (89.36) | 31/47 (65.96) | 27/47 (57.45) | 27/47 (57.45) | 0.396 | 0.396 |
| PPV (%) | 55/63 (87.3) | 52/57 (91.23) | 68/84 (80.95) | 97/117 (82.91) | 96/116 (82.76) | 0.722 | 0.743 |
| NPV (%) | 39/102 (38.24) | 42/108 (38.89) | 31/81 (38.27) | 27/48 (56.25) | 27/49 (55.1) | 0.047 | 0.061 |
| Se (%) | 55/118 (46.61) | 52/118 (44.07) | 68/118 (57.63) | 97/118 (82.20) | 96/118 (81.36) | <0.001* | <0.001* |
| Sp (%) | 67/75 (89.33) | 68/75 (90.67) | 48/75 (64.00) | 47/75 (62.67) | 47/75 (62.67) | 0.865 | 0.865 |
| PPV (%) | 55/63 (87.30) | 52/59 (88.14) | 68/95 (71.58) | 97/125 (77.60) | 96/124 (77.42) | 0.307 | 0.323 |
| NPV (%) | 67/130 (51.54) | 68/134 (50.74) | 48/98 (48.98) | 47/68 (69.12) | 47/69 (68.12) | 0.010* | 0.014* |
| Se – sensitivity; Sp – specificity; PPV – positive predictive value; NPV – negative predictive value; * significant difference ( -value refers to differences between AFP only and a combination of AFP and methylation. | |||||||